Navigation Links
KV Begins Shipping Evamist(TM) to Wholesalers
Date:4/14/2008

s, which among others, could cause actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.

Such factors include (but are not limited to) the following: (1) changes in the current and future business environment, including interest rates and capital and consumer spending; (2) the difficulty of predicting FDA approvals, including timing, and that any period of exclusivity may not be realized; (3) acceptance and demand for new pharmaceutical products; (4) the impact of competitive products and pricing, including as a result of so-called authorized-generic drugs; (5) new product development and launch, including the possibility that any product launch may be delayed or that product acceptance may be less than anticipated; (6) reliance on key strategic alliances; (7) the availability of raw materials and/or products manufactured for the Company under contract manufacturing arrangements with third parties; (8) the regulatory environment, including regulatory agency and judicial actions and changes in applicable law or regulations; (9) fluctuations in revenues; (10) the difficulty of predicting international regulatory approval, including timing; (11) the difficulty of predicting the pattern of inventory movements by the Company's customers; (12) the impact of competitive response to the Company's sales, marketing and strategic efforts; (13) risks that the Company may not ultimately prevail in litigation; (14) completion of the Company's financial statements for the first, second and third quarters of fiscal 2008; (15) actions by the Securities and Exchange Commission and the Internal Revenue Service with respect to the Company's stock option grants and accounting practices; (16) the risks detailed from time to time in the Company's filings with the Securities and Exchange Commission; and (17) the impact of credit market disruptions on the fair value of auction rate securities that we h
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. When a Mind Begins to Disappear: A Young Familys Journey to the Dark Side
2. Annual National Public Health Week Begins Today
3. Viscorp, Inc. Announces Name Change to Tianyin Pharmaceutical Co Inc. and Begins Trading Under the Ticker OTC BB: TYNP
4. As Congress Begins Debate on Bush Budget, Front-Line Caregivers Urge Rejection of Medicare Cuts
5. XTend Medical (XMDC) Begins Remote Diabetic Telehealth Program
6. High blood pressure worsening in all states for women; begins to stagnate for men
7. Parental Alienation Awareness Organization Begins Preparations for Parental Alienation Awareness Day - April 25th
8. USA TODAY to Report Special Series "Turning 62: The Retirement Boom Begins"
9. Fitness Begins at Home
10. Work Begins on New Regional Hospital Medical Campus
11. Johnson City Medical Center Begins Offering Einstein Bros. Menu Items at Second On Campus Location
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... Pitt Researchers to ... University of Pittsburgh School of Medicine are leading a five-year, $5 million initiative ... Africa. , A cooperative agreement awarded by the U.S. Agency for International ...
(Date:8/3/2015)... ... August 03, 2015 , ... Catalent ... for drugs, biologics and consumer health products, today welcomed the announcement by OPKO ... New Drug Application for a new treatment for chronic kidney disease (CKD) and ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novatus, Inc. today launched the ... as well as announced the date of its next major release. , Version ... management tasks as well as enhancements to the customer experience. Users now ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sensato ... new program “Designing Secure Healthcare Systems” This three-day, highly interactive and immersive ... healthcare organizations with access to the tactics, techniques and practices required to design ...
(Date:8/3/2015)... Angeles, CA (PRWEB) , ... August 03, 2015 , ... ... Back Pain: Injection of Stem Cells Found to Release Natural Painkiller That Can Last ... pain in patients. According to the report, the new study showed that harvesting stem ...
Breaking Medicine News(10 mins):Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Novatus Unveils Milestone Software Release 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3
... - When given alongside radiation therapy for head and ... to reduce the debilitating side effect of xerostomia, according ... Anderson Cancer Center and Fudan University Shanghai Cancer Center. ... , reported findings from the first randomized controlled trial ...
... press release is available in French . , ... metastasis has been identified by a team of researchers led by ... Health Centre (RI-MUHC). Complications in breast cancer patients are commonly caused ... of the body, most often to the bones and lungs. These ...
... Norwegians, the investigators found that alcohol consumption was associated ... from coronary artery disease. For men, the fully ... CI 0.39 - 0.69) when comparing subjects reporting more ... or rarely drinking; for women, it was 0.62 (0.3-.23). ...
... This press release is available in German . ... mirror-inverted manner. They differ from each other like a left ... is referred to as chirality is of particular relevance to ... dioxide or methane are not chiral, many biologically relevant molecules, ...
... , THURSDAY, Nov. 10 (HealthDay News) -- ,Heavy ... according to a new study. It also confirmed ... and schizophrenia. Methamphetamine and other amphetamine-type stimulants are ... worldwide. In this study, researchers at the Centre ...
... HealthDay Reporter , WEDNESDAY, Nov. 9 (HealthDay ... livers are typically subject to a mandatory six-month "dry-out" ... Unfortunately, many of the sickest of these patients fail ... that earlier transplants can dramatically improve survival odds in ...
Cached Medicine News:Health News:UT MD Anderson study finds acupuncture can prevent radiation-induced chronic dry mouth 2Health News:UT MD Anderson study finds acupuncture can prevent radiation-induced chronic dry mouth 3Health News:New target identified to stop the spread of breast cancer 2Health News:Flexible rack systems sort molecules 2Health News:Heavy Meth Use Linked to Schizophrenia 2Health News:Study Supports Shorter Wait Time for Alcoholics Seeking Liver Transplant 2Health News:Study Supports Shorter Wait Time for Alcoholics Seeking Liver Transplant 3
(Date:8/3/2015)... 2015 ReportsnReports.com adds Global ... 2020 forecasts as well as Global Medical Simulation ... intelligence collection of its library. Complete ... forecasts spread across 164 pages, talking about 7 ... figures is now available at http://www.reportsnreports.com/reports/407046-global-medical-simulation-industry-report-2015.html ...
(Date:8/3/2015)... , Aug. 3, 2015 Par Pharmaceutical Companies, ... call on Friday, August 7, 2015 at 9:00 a.m. ... second quarter ended June 30, 2015.  Par is privately ... the public in its filings with the Securities and ... on its website by following the instructions at ...
(Date:8/3/2015)... OmniSeq, LLC today announced the addition ... SM Genomic Network.  Recently, OmniSeq officially spun ... announced it was making available a suite of ... to genomic diagnostics that provides actionable results to ... rapidly expanding, multidisciplinary cancer care center that is ...
Breaking Medicine Technology:Medical Simulation Market to see 14% CAGR to 2019 2Medical Simulation Market to see 14% CAGR to 2019 3Medical Simulation Market to see 14% CAGR to 2019 4Medical Simulation Market to see 14% CAGR to 2019 5Medical Simulation Market to see 14% CAGR to 2019 6OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 2OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 3
... - ARIAD,Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that ... 2 and,1b clinical data from ongoing trials of ... meeting of the American Society,of Clinical Oncology (ASCO) ... data from the Phase 2 trial of single-agent,AP23573 ...
... May 25, 2007 /PRNewswire-FirstCall/ --,Genta Incorporated announced that several ... (gallium nitrate injection), will be presented at the,43rd annual ... Chicago, June 1-5, 2007. The abstracts include the,following: , ... Factor in Stage IV Melanoma Patients but is a, ...
Cached Medicine Technology:Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, To Be,Presented at the ASCO Annual Meeting 2Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, To Be,Presented at the ASCO Annual Meeting 3Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, To Be,Presented at the ASCO Annual Meeting 4Genta Incorporated to Present Multiple Abstracts at the Annual,Meeting of the American Society of Clinical Oncology 2Genta Incorporated to Present Multiple Abstracts at the Annual,Meeting of the American Society of Clinical Oncology 3
... From simple techniques such as submarine electrophoresis ... Step IEF, the Series 90 Programmable Power ... Series 90 Programmable Power Supplies are available ... or 6000V., All models operate in constant ...
... - 200: 200V, .01-2A. 300: 300V, 4-400mA. ... Select constant voltage or constant current ... gels. - Compact, lightweight and stackable. - ... - Ideal for DNA, RNA and protein ...
... The MAX POWER Programmable Power Supply ... which can handle virtually any application ... current blotting. It is unique in ... The MAX POWER Programmable Power Supply ...
... The e-power series power ... any horizontal gel electrophoresis system. ... constructed to the most rigorous ... recognition as the most compact ...
Medicine Products: